Rigel enrols first participant in Phase Ib/II AML treatment regimen trial [Yahoo! Finance]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Yahoo! Finance
with decitabine and venetoclax for patients with mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukaemia (AML). The multicentre, open-label, non-randomised study is sponsored and being carried out by The University of Texas MD Anderson Cancer Center (MD Anderson) in the US. The initial Phase Ib portion of the trial aims to establish the safety, tolerability, and recommended Phase II dose of oral or intravenously administered (IV) decitabine and venetoclax plus olutasidenib in mIDH1 R/R patients. Following Phase Ib, the Phase II part of the trial will involve 60 patients. This portion will focus on determining the complete remission rate among both newly diagnosed and relapsed/refractory (R/R) mIDH1 AML patients as its primary objective. REZLIDHIA is an oral small-molecule inhibitor targeting mIDH1, designed to reduce 2-hydroxyglutarate levels and promote normal differentiation of myeloid cells. It is currently approved for treating R/R mIDH1 AML. This trial is
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $40.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- Rigel to Present at the Jefferies London Healthcare ConferencePR Newswire
- Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]Yahoo! Finance
- Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Rigel Reports Third Quarter 2024 Financial Results and Provides Business UpdatePR Newswire
RIGL
Earnings
- 11/7/24 - Beat
RIGL
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 8-K
- 11/7/24 - Form 10-Q
- RIGL's page on the SEC website